BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer
BriaCell Therapeutics (NASDAQ: BCTX) has reported impressive survival data from its Phase 2 clinical study of Bria-IMT in metastatic breast cancer patients. The study showed that 52% of the most recent 25-patient cohort survived beyond one year, surpassing current standard of care expectations. Notably, 11 patients remain alive, with two remarkable cases reaching 38.3 and 30.3 months of survival.
The study included heavily pre-treated patients who had previously failed multiple therapies, including checkpoint inhibitors and antibody-drug conjugates. The median number of prior treatments was 6, and importantly, no treatment discontinuations related to Bria-IMT have been reported, suggesting a well-tolerated profile.
BriaCell Therapeutics (NASDAQ: BCTX) ha riportato dati di sopravvivenza impressionanti dal suo studio clinico di Fase 2 su Bria-IMT in pazienti con carcinoma mammario metastatico. Lo studio ha mostrato che il 52% degli ultimi 25 pazienti del gruppo ha superato un anno di sopravvivenza, superando le aspettative degli standard di cura attuali. In particolare, 11 pazienti sono ancora vivi, con due casi eccezionali che hanno raggiunto rispettivamente 38,3 e 30,3 mesi di sopravvivenza.
Lo studio ha incluso pazienti fortemente pretrattati che avevano precedentemente fallito molteplici terapie, inclusi inibitori del checkpoint e coniugati anticorpo-farmaco. Il numero mediano di trattamenti precedenti era 6 e, cosa importante, non sono state segnalate interruzioni del trattamento correlate a Bria-IMT, suggerendo un profilo ben tollerato.
BriaCell Therapeutics (NASDAQ: BCTX) ha informado datos impresionantes de supervivencia en su estudio clínico de Fase 2 con Bria-IMT en pacientes con cáncer de mama metastásico. El estudio mostró que el 52% de la cohorte más reciente de 25 pacientes sobrevivió más de un año, superando las expectativas del estándar actual de atención. Cabe destacar que 11 pacientes siguen vivos, con dos casos notables que alcanzaron 38,3 y 30,3 meses de supervivencia.
El estudio incluyó pacientes con tratamientos previos intensivos que habían fallado múltiples terapias, incluyendo inhibidores de puntos de control y conjugados anticuerpo-fármaco. El número medio de tratamientos previos fue 6 y, lo que es importante, no se han reportado interrupciones del tratamiento relacionadas con Bria-IMT, lo que sugiere un perfil bien tolerado.
BriaCell Therapeutics (NASDAQ: BCTX)� 전이� 유방� 환자� 대상으� � Bria-IMT 2� 임상시험에서 인상적인 생존 데이터를 보고했습니다. 연구 결과 최근 25� 환자 그룹� 52%가 1� 이상 생존하여 현재 표준 치료 기대치를 뛰어넘었습니�. 특히 11명의 환자가 여전� 생존 �이며, � 명의 주목� 만한 사례� 각각 38.3개월� 30.3개월� 생존 기간� 기록했습니다.
� 연구� 체크포인� 억제� � 항체-약물 접합� � 여러 치료� 실패� 다중 치료 경험� 있는 환자들을 포함했습니다. 이전 치료 횟수� 중앙값은 6회였으며, 중요� 점은 Bria-IMT와 관련된 치료 중단 사례가 보고되지 않아 내약성이 우수함을 시사합니�.
BriaCell Therapeutics (NASDAQ : BCTX) a publié des données impressionnantes sur la survie issues de son étude clinique de phase 2 avec Bria-IMT chez des patientes atteintes d’un cancer du sein métastatique. L’étude a montré que 52 % de la cohorte la plus récente de 25 patientes ont survécu au-delà d’un an, dépassant les attentes des standards actuels de soins. Notamment, 11 patientes sont toujours en vie, avec deux cas remarquables atteignant respectivement 38,3 et 30,3 mois de survie.
L’étude a inclus des patientes fortement prétraitées ayant échoué à plusieurs thérapies, y compris des inhibiteurs de points de contrôle et des conjugués anticorps-médicaments. Le nombre médian de traitements antérieurs était de 6 et, fait important, aucune interruption de traitement liée à Bria-IMT n’a été rapportée, suggérant un profil bien toléré.
BriaCell Therapeutics (NASDAQ: BCTX) hat beeindruckende Überlebensdaten aus seiner Phase-2-Studie mit Bria-IMT bei Patienten mit metastasiertem Brustkrebs veröffentlicht. Die Studie zeigte, dass 52 % der jüngsten Kohorte von 25 Patienten länger als ein Jahr überlebten, was die Erwartungen der aktuellen Standardbehandlung übertrifft. Bemerkenswert ist, dass 11 Patienten noch am Leben sind, wobei zwei außergewöhnliche Fälle Überlebenszeiten von 38,3 und 30,3 Monaten erreichten.
Die Studie umfasste stark vorbehandelte Patienten, die zuvor mehrere Therapien, einschließlich Checkpoint-Inhibitoren und Antikörper-Wirkstoff-Konjugate, nicht erfolgreich durchlaufen hatten. Die mediane Anzahl vorheriger Behandlungen lag bei 6, und wichtig ist, dass keine behandlungsbedingten Abbrüche im Zusammenhang mit Bria-IMT gemeldet wurden, was auf ein gut verträgliches Profil hinweist.
- 52% one-year survival rate exceeds standard of care expectations
- 11 patients still alive, with longest survival reaching 38.3 months
- No Bria-IMT-related treatment discontinuations reported
- Effective in heavily pre-treated patients who failed other advanced therapies
- Final median overall survival data still pending for some sub-populations
- Study conducted in a relatively small patient cohort (25 patients)
- Results from single-arm trial, not yet compared in randomized setting
Insights
BriaCell's Bria-IMT shows promising 52% one-year survival in heavily pre-treated metastatic breast cancer patients, outperforming standard care comparisons.
The Phase 2 data from BriaCell's Bria-IMT therapy represents a significant clinical development in the metastatic breast cancer space. The 52% one-year survival rate stands out particularly because these patients had already failed an average of 6 prior treatment regimens, including advanced therapies like checkpoint inhibitors and antibody-drug conjugates (TRODELVY® and ENHERTU®).
Contextualizing these results against comparative one-year survival rates is crucial. The study population's 52% rate substantially outperforms benchmarks from similar patient populations: Cortes et al. (~38-40%), Kazmi et al. (30-38%), and especially the TNBC subpopulation in Bardia et al. (~23%). The durability of response in some patients is particularly noteworthy, with extended survival reaching 38.3 months and 30.3 months in two patients.
The treatment's safety profile appears favorable with no Bria-IMT-related discontinuations reported - a meaningful advantage in a heavily pre-treated population where treatment toxicity often limits therapeutic options. The ongoing pivotal Phase 3 study (NCT06072612) using the same formulation will be the definitive test of efficacy, as Phase 2 results, while promising, come from a single-arm study with inherent limitations in directly proving causality.
This survival signal in patients who have exhausted standard treatments, including modern immunotherapies and ADCs, suggests Bria-IMT may offer a mechanistically distinct approach to overcoming treatment resistance in advanced breast cancer.
52% of BriaCell’s most-recent 25-patient cohort* have surpassed the one-year survival milestone, exceeding current standard of care in similar patients- 11 patients remain alive as of recent contact, including one patient at 38.3 months and another at 30.3 months
- Survival benefit observed in heavily pre-treated patients, including those who failed treatment with checkpoint inhibitors (CPIs) and antibody-drug conjugates (ADCs)
PHILADELPHIA and VANCOUVER, British Columbia, July 08, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell� or the “Company�), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, has reported updated survival data from its ongoing Phase 2 clinical study of Bria-IMT in patients with metastatic breast cancer (MBC).
- BriaCell’s most recent Phase 2 study cohort of 25 patients* achieved a
52% one-year survival rate (i.e.52% of patients remained alive at least one year after starting on the study). - 11 of these patients remain alive as of most recent contact, including one patient at 38.3 months and another at 30.3 months (see Table 1).
- Survival rate exceeds the survival expectations with the current standard of care therapies in similar patient populations (see Table 2).
- Notably, many patients had very advanced metastatic breast cancer, having already failed multiple prior lines of therapy including check point inhibitors (CPIs) and antibody-drug conjugates (ADCs) such as TRODELVY® - (sacituzumab govitecan-hziy) and ENHERTU® (fam-trastuzumab - deruxtecan-nxki).
- No treatment discontinuations attributed to Bria-IMT have been reported.
Table 1: Select Long-Term Responders | ||||
Patient | Months Survival | Age | Prior Regimens | Cycles of Bria-IMT |
01-009 | 38.3 | 74 | 5 | 13 |
07-001 | 30.3 | 55 | 7; including ENHERTU | 8 |
11-018 | 21.6 | 66 | 8 | 28 |
11-019 | 20.0 | 63 | 9; including TRODELVY | 6 |
16-003 | 19.4 | 80 | 5; including ENHERTU | 8 |
“BriaCell’s Phase 2 data indicate a robust survival signal and a well-tolerated profile,� stated Adam M. Brufsky, MD, PhD, FACP, Professor of Medicine at the University of Pittsburgh School of Medicine and Medical Director of the Magee-Women's Cancer Program. “These results reinforce BriaCell’s potential to improve survival and tolerability for late-stage patients.�
“Many patients with metastatic breast cancer unfortunately have disease progression despite treatment with CPIs and ADCs,� added Aditya Bardia, MD, MPH, FASCO, a leading breast cancer expert. “BriaCell’s survival data in single arm Phase 2 trial highlights the potential activity of Bria-IMT in combination with CPIs and is subject to ongoing investigation in a Phase 3 randomized clinical trial in MBC.�
Table 2: Comparable Analysis of One-Year Survival | ||||
Reference | Breast Cancer Type | Median prior lines of therapy | Percent Survival at 1 year | |
Bria-IMT plus CPI | All types: | 6 | ||
Cortes et al.1 | All types: 18 18 | 4 | ~38 | |
Kazmi et al.2 | All types: 51 25 9 | 2 | 30 | |
Bardia et al. (TPC arm)3 | TNBC | 2-3 | ~ | |
Rugo et al (TPC arm)4 | HR+ HER2- | 2 | ||
* 25 patients treated with the Phase 3 formulation since 2022
| ||||
Abbreviations:
HR+: hormone receptor-positive
TNBC: Triple-negative breast cancer (lacks or has low levels of the estrogen receptor, progesterone receptor, and human epidermal growth factor 2 (HER2))
HER2+: Human epidermal growth factor receptor 2 positive
HR+ HER2-: hormone receptor-positive and human epidermal growth factor receptor 2 negative
TPC: Treatment of Physicians Choice
BriaCell’s Phase 2 study enrolled 54 heavily pre-treated metastatic breast cancer patients (median number of prior treatments = 6) who received the Bria-IMT regimen plus checkpoint inhibitor. Of these 54 patients, 37 were treated with the formulation currently being used in BriaCell’s ongoing pivotal Phase 3 study in metastatic breast cancer (listed on ClinicalTrials.gov as). Final median overall survival calculation for the Phase 2 study is pending for some sub populations as many patients remain alive. No Bria-IMT-related discontinuations have been reported to date.
About BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at .
Safe Harbor
This press release contains “forward-looking statements� that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,� “believe,� “contemplate,� “could,� “estimate,� “expect,� “intend,� “seek,� “may,� “might,� “plan,� “potential,� “predict,� “project,� “target,� “aim,� “should,� “will,� “would,� or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including statements about: BriaCell’s potential to improve survival and tolerability for late-stage metastatic breast cancer patients; the impact of Bria-IMT� on patients with metastatic breast cancer; and BriaCell’s further clinical development of Bria-IMT� are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties� in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors� in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties� in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at and on EDGAR at . Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
Investor Relations Contact:
